Provided by Tiger Fintech (Singapore) Pte. Ltd.

INmune Bio Inc

1.82
0.0000
Post-market: 1.890.0700+3.85%19:59 EDT
Volume:321.48K
Turnover:588.32K
Market Cap:48.39M
PE:-0.72
High:1.89
Open:1.83
Low:1.79
Close:1.82
52wk High:11.64
52wk Low:1.71
Shares:26.59M
Float Shares:20.18M
Volume Ratio:1.04
T/O Rate:1.59%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.5162
EPS(LYR):-2.1100
ROE:-168.34%
ROA:-55.08%
PB:1.68
PE(LYR):-0.86

Loading ...

INmune Bio Inc expected to post a loss of 32 cents a share - Earnings Preview

Reuters
·
Yesterday

INmune Bio Inc. to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on Thursday, October 30, 2025

GlobeNewswire
·
Oct 23

INmune Bio to Participate in Dermatologic Rare Disease Panel at the Maxim Growth Summit 2025

GlobeNewswire
·
Oct 14

INmune Bio Inc. Announces Date for Upcoming Special Meeting of Stockholders

Reuters
·
Oct 04

INmune Bio submits Phase 2 MINDFuL trial results to npj Dementia

TIPRANKS
·
Sep 29

INmune Bio Announces Positive Phase 2 MINDFuL Trial Results for XPro™ in Early Alzheimer’s Disease with Inflammation

Reuters
·
Sep 29

INmune Bio Announces Submission of Phase 2 Mindful Trial Results in Alzheimer’s Disease to Npj Dementia, a Nature Portfolio Journal

THOMSON REUTERS
·
Sep 29

INmune Bio Inc - on Track for Maa Filing in UK in H1 2026 Followed by Bla in US

THOMSON REUTERS
·
Sep 15

INmune Bio Announces Successful Completion of First Commercial Pilot-Scale Manufacturing Run of CORDStrom™ at CGT Catapult

GlobeNewswire
·
Sep 15

INmune Bio Inc. Files Initial Beneficial Ownership Statement for Interim CFO Cory Randall Ellspermann

Reuters
·
Aug 19

INmune Bio Inc reports results for the quarter ended June 30 - Earnings Summary

Reuters
·
Aug 08

INmune Bio Q2 EPS $(1.05) Misses $(0.40) Estimate

Benzinga
·
Aug 08

INmune Bio Inc: Q2 EPS $-1.05

THOMSON REUTERS
·
Aug 08

INmune Bio Inc - Kelly Ganjei Appointed Chairman of the Board

THOMSON REUTERS
·
Aug 08

INmune Bio Inc - Cory Ellspermann Appointed Interim CFO

THOMSON REUTERS
·
Aug 08

INmune Bio Inc - David Moss Appointed President & CEO

THOMSON REUTERS
·
Aug 08

INmune Bio Inc: End of Phase 2 Meeting Regarding Mindful Trial With FDA Expected to Take Place in Q4

THOMSON REUTERS
·
Aug 08

INmune Bio Inc. Announces Second Quarter 2025 Results, Provides Business Update and Announces Management Changes

GlobeNewswire
·
Aug 08

INmune Bio Inc expected to post a loss of 38 cents a share - Earnings Preview

Reuters
·
Aug 06

BUZZ-U.S. STOCKS ON THE MOVE-Tyson Foods, BioNTech, Gold miners

Reuters
·
Aug 04